Antimicrobial peptide AMP-17 induces protection against systemic candidiasis and interacts synergistically with fluconazole against <i>Candida albicans</i> biofilm.

ABSTRACT: Candida albicans, a common commensal and opportunistic fungal pathogen in humans, can occasionally progress to disseminated candidiasis which is a serious condition with a high morbidity and fatality rate. The emergence of drug-resistant fungal strains compels us to look for an efficient treatment solution. Our earlier studies have demonstrated that the unique antimicrobial peptide AMP-17 from Musca domestica has a strong antifungal impact on C. albicans in vitro. Here, we verified the therapeutic effects of AMP-17 on systemic candidiasis in vivo and the peptide interacts with fluconazole, a common antifungal medication, to treat systemic candidiasis. In the disseminated candidiasis model of Galleria mellonella and mice challenged with C. albicans,

SUBMITTER: Sun C 

PROVIDER: S-EPMC11564183 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature